Vanguard Portfolio Management
PTGX icon

Vanguard Portfolio Management’s Protagonist Therapeutics PTGX Stock Holding History

Vanguard Portfolio Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445M Buy
3,629,298
+148,087
+4% +$15.5M 0.02% 772
2026
Q1 		$367M Buy
+3,481,211
New +$308M 0.02% 792

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM

Vanguard Portfolio Management's PTGX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Protagonist Therapeutics (PTGX) stake by 4.3% in Q2 2026, buying an estimated $15.5M and bringing the position to 3,629,298 shares worth $445M. The position accounts for 0.02% of the portfolio, ranked #772.

Vanguard Portfolio Management first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vanguard Portfolio Management held 3,629,298 shares of Protagonist Therapeutics worth $445M as of Q2 2026.
  • Vanguard Portfolio Management bought 148,087 Protagonist Therapeutics shares in Q2 2026, an estimated $15.5M.
  • Protagonist Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q2 2026, its #772 holding.
  • Vanguard Portfolio Management first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.